Device Trial Radar · NCT04902248
OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
236
Planned (sponsor's estimate)
Start
Nov 27, 2021
Primary completion
Sep 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Chinese University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 26, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the management of patients with acute upper non-variceal upper gastrointestinal bleeding, further bleeding is the most important adverse factor predictive of mortality. In the United Kingdom Audit on acute upper gastrointestinal bleeding, clinical evidence of further bleeding was reported in 13% of patients following the first endoscopy and 27% of them died. The use of OTSC has emerged as an alternative before angiographic embolization(TAE) which is often considered most definitive. We propose to define the algorithm in the management of patients with refractory bleeding from their peptic ulcers or other non variceal causes. We hypothesize that endoscopic use of OTSC compares favourably with TAE and both lead to similar outcomes. An equivalence of the two modalities may mean that endoscopic application of OTSC should be attempted before TAE as often we need to document further bleeds with endoscopy and a second treatment should be instituted at the same time.
Conditions
- Upper Gastrointestinal Bleeding
Interventions
The OTSC® System SetDevice
The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion
angiographic embolizationProcedure
Transcatheter selective embolization to bleeding arteries
Primary outcomes
What the sponsor says the trial is designed to measure.
- further bleedingTime frame: within 30 days after randomization
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Beijing friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
the First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Huaxi Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.